Doherty Ann Sinéad, Lund Lars Christian, Moriarty Frank, Boland Fiona, Clyne Barbara, Fahey Tom, Kennelly Seán P, O'Mahony Denis, Wallace Emma
Department of General Practice, School of Medicine, University College Cork, Cork, Ireland
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Ann Fam Med. 2025 Jul 28;23(4):315-324. doi: 10.1370/afm.240383.
Prescribing cascades occur when one medication is used to treat adverse effects of another medication. Older adults with polypharmacy are at higher risk for this phenomenon. We examined the prevalence, magnitude, and effect modification of 9 prescribing cascades (ThinkCascades) among older community-dwelling adults in a national prescription database.
We used prescription sequence symmetry analysis to examine prescriptions for ThinkCascades medications dispensed in primary care under the General Medical Services scheme in Ireland. Analyses were based on prescriptions dispensed between 2017 and 2020 among 533,464 adults aged 65 years or older. Incident users of both medications in each ThinkCascades dyad were included. We used an observation window of 365 days and examined other windows in sensitivity analyses. Adjusted sequence ratios (aSRs) took into account secular prescribing trends. We also conducted analyses stratified by sex, age, and individual index medication.
Five prescribing cascades had significant positive aSRs, indicating that the patient was more likely to receive the index medication before the marker medication. The largest signal was identified for the calcium channel blocker to diuretic cascade (prevalence, 2.6%; aSR = 1.93; 95% CI, 1.79-2.09). Positive signals were also identified for the -receptor blocker to vestibular sedative cascade (prevalence, 3.0%; aSR = 1.63; 95% CI, 1.46-1.81); the selective serotonin reuptake inhibitor/selective norepinephrine reuptake inhibitor to sleep medication cascade (prevalence, 2.5%; aSR = 1.54; 95% CI, 1.40-1.69); the antipsychotic to antiparkinsonian cascade (prevalence, 0.4%; aSR = 1.20; 95% CI, 1.00-1.43); and the benzodiazepine to antipsychotic cascade (prevalence, 3.2%; aSR = 1.15; 95% CI, 1.08-1.21).
To our knowledge, this study is the first to describe the prevalence of an expert consensus-based list of prescribing cascades, ThinkCascades, in a national population of older adults, and it identified 5 clinically relevant prescribing cascades. These findings highlight prescribing cascades as an important underresearched area contributing to complex polypharmacy among older people living with multimorbidity.
当一种药物用于治疗另一种药物的不良反应时,就会出现处方级联现象。服用多种药物的老年人出现这种现象的风险更高。我们在一个国家处方数据库中,研究了社区居住的老年成年人中9种处方级联(ThinkCascades)的患病率、严重程度及效应修正情况。
我们采用处方序列对称性分析,来研究爱尔兰综合医疗服务计划下基层医疗中发放的ThinkCascades药物的处方情况。分析基于2017年至2020年期间533464名65岁及以上成年人的处方发放情况。纳入了每个ThinkCascades药物对中两种药物的新使用者。我们使用了365天的观察窗口,并在敏感性分析中研究了其他窗口。调整后的序列比(aSRs)考虑了长期的处方趋势。我们还按性别、年龄和个别索引药物进行了分层分析。
五种处方级联具有显著的正向aSRs,表明患者在使用标记药物之前更有可能接受索引药物。钙通道阻滞剂到利尿剂的级联信号最强(患病率为2.6%;aSR = 1.93;95% CI,1.79 - 2.09)。β受体阻滞剂到前庭镇静剂的级联也有正向信号(患病率为3.0%;aSR = 1.63;95% CI,1.46 - 1.81);选择性5-羟色胺再摄取抑制剂/选择性去甲肾上腺素再摄取抑制剂到睡眠药物的级联(患病率为2.5%;aSR = 1.54;95% CI,1.40 - 1.69);抗精神病药物到抗帕金森病药物的级联(患病率为0.4%;aSR = 1.20;95% CI,1.00 - 1.43);以及苯二氮䓬类药物到抗精神病药物的级联(患病率为3.2%;aSR = 1.15;95% CI,1.08 - 1.21)。
据我们所知,本研究首次描述了在全国老年人群中基于专家共识的处方级联清单ThinkCascades的患病率,并确定了5种与临床相关的处方级联。这些发现凸显了处方级联是一个重要但研究不足的领域,它导致了患有多种疾病的老年人复杂的多重用药情况。